GeneDx Holdings Corp.

GeneDx is an American biotechnology company specializing in genomic diagnostics, with a core mission to empower individuals to live their healthiest lives through genomics. The company delivers improved health outcomes by providing genomic and clinical insights, primarily focusing on the diagnosis of rare and inherited disorders. GeneDx is headquartered in Stamford, Connecticut, with its clinical laboratory operations located in Gaithersburg, Maryland.

The company's key offerings include genetic testing services, with a primary emphasis on whole exome sequencing (WES) and whole genome sequencing (WGS). These services are utilized by healthcare providers, hospitals, and health systems, particularly for rare and ultra-rare diseases in pediatric genetics, neurology, and critical-care settings. GeneDx also provides rapid sequencing options for critically ill pediatric and neonatal patients. A significant asset is GeneDx Infinity, one of the world's largest rare disease datasets, which is leveraged for advanced interpretation, drug discovery, and to convert complex genomic data into actionable clinical answers.

Katherine Stueland serves as the Chief Executive Officer, and Mark Gardner was appointed President effective June 15, 2026. In recent news, GeneDx reported its Q1 2026 financial results on May 4, 2026. The company is currently facing class-action lawsuits alleging that it and its executives made misleading statements regarding the benefits of the Fabric Genomics acquisition, which closed in May 2025, and its impact on financials. GeneDx aims to position exome and genome sequencing as a standard of care earlier in clinical workups, leveraging its extensive genomic data and expertise to lead in rare disease diagnosis.